Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Covetrus, Inc.    CVET


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Covetrus : Appoints Sandi Peterson to Its Board of Directors

06/11/2020 | 08:32am EST

Peterson, who currently serves as an operating partner at Clayton, Dubilier & Rice, brings a wealth of global healthcare and consumer experience to the company’s board

Covetrus™ (NASDAQ: CVET), a global leader in animal-health technology and services, announced today that Sandra E. Peterson has been appointed to the company’s board of directors. The appointment increases the number of directors serving on the Covetrus board to ten.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200611005217/en/

Covetrus appoints Sandi Peterson, of Clayton, Dubilier & Rice, to its board of directors. (Photo: Business Wire)

Covetrus appoints Sandi Peterson, of Clayton, Dubilier & Rice, to its board of directors. (Photo: Business Wire)

“Sandi’s wealth of experience in large, global businesses that span the intersection of healthcare, consumer and technology makes her the perfect addition to the Covetrus board," said Philip A. Laskawy, Covetrus chairman of the board. “We welcome her perspective and experience in driving operational improvement during periods of transformation as Covetrus continues to execute against its strategic growth objectives and create shareholder value.”

Ms. Peterson has had a long and successful career of driving growth, operational improvement and innovation across global healthcare and consumer businesses. This includes executive roles at Johnson & Johnson, where she was group worldwide chairman, led the consumer and medical devices businesses and was responsible for the corporation’s global supply chain, technology strategy and infrastructure, and at Bayer, where she held numerous positions including the CEO of Bayer CropScience AG, CEO of Bayer Medical Care and president of Bayer HealthCare AG’s Diabetes Care Division. She started her career at McKinsey and has held executive positions at Medco Health Solutions, Nabisco, and Whirlpool. Currently, she is an operating partner at CD&R, a leading private investment firm, is a member of the Microsoft Board of Directors and is on the board of trustees of the Institute for Advanced Study and the American Academy in Berlin. She has appeared on Fortune magazine’s list of most powerful women numerous times and was featured on the magazine’s inaugural list of leaders changing healthcare.

“Covetrus plays an integral role in the attractive global animal-health market and I am excited for the opportunity to leverage my experience to provide additional perspectives and insights as the company continues to transform its business at an accelerated pace," said Sandi Peterson. "I look forward to being a part of the board and working with the management team to help drive further operational excellence and shareholder value creation.”

Ms. Peterson holds an M.P.A. in applied economics from Princeton University and a B.A. in government from Cornell University.

About Covetrus

Covetrus is a global animal-health technology and services company dedicated to empowering veterinary practice partners to drive improved health and financial outcomes. We are bringing together products, services, and technology into a single platform that connects our customers to the solutions and insights they need to work best. Our passion for the well-being of animals and those who care for them drives us to advance the world of veterinary medicine. Covetrus is headquartered in Portland, Maine with more than 5,500 employees serving over 100,000 customers around the globe. For more information about Covetrus visit https://covetrus.com/.

Forward-Looking Statements

This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including statements about our plans, objectives, expectations, and intentions. Such statements are subject to numerous risks and uncertainties. Factors that could adversely affect our business and prospects are set forth in our public filings with the Securities and Exchange Commission. Our forward-looking statements are based on current beliefs and expectations of our management team and, except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise. Investors are cautioned not to place undue reliance on these forward-looking statements.

© Business Wire 2020
All news about COVETRUS, INC.
11/18COVETRUS, INC. : Submission of Matters to a Vote of Security Holders, Regulation..
11/10COVETRUS : Management's Discussion and Analysis of Financial Condition and Resul..
11/10COVETRUS : 3Q Earnings Snapshot
11/10COVETRUS, INC. : Results of Operations and Financial Condition, Financial Statem..
11/10COVETRUS : Announces Financial Results for Third Quarter of 2020
11/10Covetrus Announces Financial Results for Third Quarter of 2020
10/27COVETRUS : Announces Third Quarter 2020 Earnings Release Date and Conference Cal..
10/27Covetrus Announces Third Quarter 2020 Earnings Release Date and Conference Ca..
10/09COVETRUS : Makes a Strategic Investment in Veterinary Study Groups, the Premier ..
09/28COVETRUS : Holds Virtual VetSummit Conference - October 16-18
More news
Financials (USD)
Sales 2020 4 272 M - -
Net income 2020 -23,0 M - -
Net Debt 2020 675 M - -
P/E ratio 2020 -111x
Yield 2020 -
Capitalization 3 391 M 3 391 M -
EV / Sales 2020 0,95x
EV / Sales 2021 0,88x
Nbr of Employees 5 300
Free-Float 72,5%
Duration : Period :
Covetrus, Inc. Technical Analysis Chart | CVET | US22304C1009 | MarketScreener
Technical analysis trends COVETRUS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 27,00 $
Last Close Price 26,59 $
Spread / Highest target 16,6%
Spread / Average Target 1,54%
Spread / Lowest Target -24,8%
EPS Revisions
Benjamin C. Wolin President, Chief Executive Officer & Director
Philip A. Laskaway Chairman
Matthew J. Foulston Chief Financial Officer
Georgina Wraight President-Global Technology Solutions & EVP
Steve Palmucci Global Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
COVETRUS, INC.101.44%3 391
MEDTRONIC PLC-0.12%151 957